Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2016 2
2019 3
2020 4
2021 2
2022 7
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, Batlevi CL, Campbell P, Ribrag V, Damaj GL, Dickinson M, Jurczak W, Kazmierczak M, Opat S, Radford J, Schmitt A, Yang J, Whalen J, Agarwal S, Adib D, Salles G. Morschhauser F, et al. Among authors: batlevi cl. Lancet Oncol. 2020 Nov;21(11):1433-1442. doi: 10.1016/S1470-2045(20)30441-1. Epub 2020 Oct 6. Lancet Oncol. 2020. PMID: 33035457 Free PMC article. Clinical Trial.
Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.
Shouval R, Alarcon Tomas A, Fein JA, Flynn JR, Markovits E, Mayer S, Olaide Afuye A, Alperovich A, Anagnostou T, Besser MJ, Batlevi CL, Dahi PB, Devlin SM, Fingrut WB, Giralt SA, Lin RJ, Markel G, Salles G, Sauter CS, Scordo M, Shah GL, Shah N, Scherz-Shouval R, van den Brink M, Perales MA, Palomba ML. Shouval R, et al. Among authors: batlevi cl. J Clin Oncol. 2022 Feb 1;40(4):369-381. doi: 10.1200/JCO.21.02143. Epub 2021 Dec 3. J Clin Oncol. 2022. PMID: 34860572 Free PMC article.
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.
Alarcon Tomas A, Fein JA, Fried S, Flynn JR, Devlin SM, Fingrut WB, Anagnostou T, Alperovich A, Shah N, Fraint E, Lin RJ, Scordo M, Batlevi CL, Besser MJ, Dahi PB, Danylesko I, Giralt S, Imber BS, Jacoby E, Kedmi M, Nagler A, Palomba ML, Roshal M, Salles GA, Sauter C, Shem-Tov N, Shimoni A, Yahalom J, Yerushalmi R, Shah GL, Avigdor A, Perales MA, Shouval R. Alarcon Tomas A, et al. Among authors: batlevi cl. Leukemia. 2023 Jan;37(1):154-163. doi: 10.1038/s41375-022-01739-2. Epub 2022 Nov 5. Leukemia. 2023. PMID: 36335261 Free PMC article.
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
Roddie C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, Zhang Y, Hu Y, Peddareddigari VGR, Khokhar N, Chen R, Basilico S, Raymond M, Vargas FA, Duffy K, Brugger W, O'Reilly MA, Wood L, Linch DC, Peggs KS, Bachier C, Budde EL, Lee Batlevi C, Bartlett N, Irvine D, Tholouli E, Osborne W, Ardeshna KM, Pule MA. Roddie C, et al. Among authors: lee batlevi c. Blood. 2023 May 18;141(20):2470-2482. doi: 10.1182/blood.2022018598. Blood. 2023. PMID: 36821767 Free PMC article.
Retrospective characterization of nodal marginal zone lymphoma.
Stuver R, Drill E, Qualls D, Okwali M, Lee Batlevi C, Caron PC, Dogan A, Epstein-Peterson ZD, Falchi L, Hamlin PA, Horwitz SM, Imber BS, Intlekofer AM, Johnson WT, Khan N, Kumar A, Lahoud OB, Lue JK, Matasar MJ, Moskowitz AJ, Noy A, Owens CN, Palomba ML, Schöder H, Vardhana SA, Yahalom J, Zelenetz AD, Salles G, Straus DJ. Stuver R, et al. Among authors: lee batlevi c. Blood Adv. 2023 Sep 12;7(17):4838-4847. doi: 10.1182/bloodadvances.2022009587. Blood Adv. 2023. PMID: 37307213 Free PMC article. Review.
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, Ghosh N, Modi D, Sabry W, Naik S, Mehta A, Nakhoda SK, Smith SD, Dorritie K, Jia T, Pham S, Huw LY, Jing J, Wu H, Ead WS, To I, Batlevi CL, Wei MC, Chavez JC. Budde LE, et al. Among authors: batlevi cl. Nat Med. 2024 Jan;30(1):229-239. doi: 10.1038/s41591-023-02726-5. Epub 2023 Dec 10. Nat Med. 2024. PMID: 38072960 Free PMC article. Clinical Trial.
Novel immunotherapies in lymphoid malignancies.
Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Batlevi CL, et al. Nat Rev Clin Oncol. 2016 Jan;13(1):25-40. doi: 10.1038/nrclinonc.2015.187. Epub 2015 Nov 3. Nat Rev Clin Oncol. 2016. PMID: 26525683 Free PMC article. Review.
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.
Erazo T, Evans CM, Zakheim D, Chu KL, Refermat AY, Asgari Z, Yang X, Da Silva Ferreira M, Mehta S, Russo MV, Knezevic A, Zhang XP, Chen Z, Fennell M, Garippa R, Seshan V, de Stanchina E, Barbash O, Batlevi CL, Leslie CS, Melnick AM, Younes A, Kharas MG. Erazo T, et al. Among authors: batlevi cl. Nat Commun. 2022 Sep 27;13(1):5676. doi: 10.1038/s41467-022-33137-8. Nat Commun. 2022. PMID: 36167829 Free PMC article.
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.
Ptashkin RN, Ewalt MD, Jayakumaran G, Kiecka I, Bowman AS, Yao J, Casanova J, Lin YD, Petrova-Drus K, Mohanty AS, Bacares R, Benhamida J, Rana S, Razumova A, Vanderbilt C, Balakrishnan Rema A, Rijo I, Son-Garcia J, de Bruijn I, Zhu M, Lachhander S, Wang W, Haque MS, Seshan VE, Wang J, Liu Y, Nafa K, Borsu L, Zhang Y, Aypar U, Suehnholz SP, Chakravarty D, Park JH, Abdel-Wahab O, Mato AR, Xiao W, Roshal M, Yabe M, Batlevi CL, Giralt S, Salles G, Rampal R, Tallman M, Stein EM, Younes A, Levine RL, Perales MA, van den Brink MRM, Dogan A, Ladanyi M, Berger MF, Brannon AR, Benayed R, Zehir A, Arcila ME. Ptashkin RN, et al. Among authors: batlevi cl. Nat Commun. 2023 Oct 28;14(1):6895. doi: 10.1038/s41467-023-42585-9. Nat Commun. 2023. PMID: 37898613 Free PMC article.
26 results